Emerging evidence and treatment paradigm of non-small cell lung cancer.

"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsYi-Long Wu discloses the following personal financial interests: Consulting and advisory services, speaking engagements of Roche, AstraZeneca, Eli Lilly, Boehringer Ingelheim, Sanofi, MSD, and BMS. The other authors have no conflict of interest. Competing interests Yi-Long Wu discloses the following personal financial interests: Consulting and advisory services, speaking engagements of Roche, AstraZeneca, Eli Lilly, Boehringer Ingelheim, Sanofi, MSD, and BMS. The other authors have no conflict of interest."

"Funding This work was supported by National Natural Science Foundation of China (Grant No. 82202997 to S.Y.M. L.), China Postdoctoral Science Foundation (No. 2021M701422 to S.Y.M. L.), Key Lab System Project of Guangdong Science and Technology Department, Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer (Grant No. 2017B030314120 to Y.L.W.), and Guangdong Provincial People's Hospital Scientific Research Funds for Leading Medical Talents in Guangdong Province (Grant No. KJ012019426 to Y.L.W.), National Natural Science Foundation of China (Grant No. 82002413 to Dr. Si-Yang Liu)."